Health Disparity Priorities

Diverse Health Hub prioritizes educational programs that address health inequity in the realm of five distinct therapeutic areas.

Each category below has specific programs tailored for both patients and providers.

Sickle Cell

Sickle cell disease is caused by a mutation with millions of people affected worldwide. Sickle cell is more common among people of certain ancestries, including those of African, Caribbean, Middle Eastern, Eastern Mediterranean, and Asian descent. Many disparities have been noted in the study of sickle cell disease. Through a series of educational programs, Diverse Health Hub will spotlight these important issues.

Kidney Cancer

Renal medullary carcinoma (RMC) is a very rare, aggressive, difficult to treat kidney cancer that predominantly impacts young people of African descent carrying the sickle cell trait or sickle cell disease. With many disparities already existing in sickle cell disease, Diverse Health Hub has made it our priority to spotlight this rare cancer for patients and families impacted by RMC.

Multiple Myeloma

Multiple myeloma is a blood disorder that begins in the plasma cells. Studies have shown that minority populations are at an elevated risk for myeloma, yet are unrepresented in research. Through a series of educational programs, Diverse Health Hub will spotlight important news impacting myeloma patients and their families.

Breast Cancer

Breast cancer survival and screening rates have improved significantly. However, incidence rates are higher among women of color and more often than not, these women are diagnosed at a later stage. Disparities in breast cancer underserved communities hinge on differences in access to care and disease awareness, but there is more to the story. Through a series of educational programs, Diverse Health Hub will spotlight important issues around breast cancer health equity related news to keep patients and families in the know.

Clinical Trials

Clinical trials are responsible for numerous advancements in medicine and cures for a multitude of diseases. Trials continue to be the key to helping experts deliver tomorrow's medicine today, the bridge to what's next. Evidence has shown that, Hispanics, Asians and African-Americans are not adequately represented in clinical trials in the US. Researchers are now exploring whether various populations respond differently to treatment and what bearing this has on potential treatment strategies. Through a series of educational programs, Diverse Health Hub will highlight important topics around trial participation.

© 2020 Diverse Health Hub